Answers are grounded in this paper and cite their sources.
Purpose: Limited real-world data exist on care patterns in peripheral T-cell lymphoma (PTCL) patients. We report care patterns and outcomes among PTCL patients in France, the United Kingdom (UK), Germany, and Italy in the first-line setting. Patients and Methods: A retrospective chart review was undertaken for adults with newly diagnosed PTCL. Eligible patients received ≥ 1 line of therapy (LOT) and had clinical data for ≥ 1 year after diagnosis or until death. Outcomes included treatments, best response at the end of 1LOT, progression-free survival (PFS) and overall survival (OS). Results: Data from 195 patients (France=53; UK=56; Germany=56; Italy=30) were collected. Median age at diagnosis was 62.0 years, with 73.3% at stage III/IV. The most common histological subtype was PTCL–not otherwise specified (36.9%). For 1LOT, 49.7% and 36.4% of patients received CHOP and CHOEP regimens, respectively. A complete response was reported in 59.7% of patients. Median PFS from 1LOT initiation was 49.4 months; median OS was 77.1 months. First-line treatment costs were highest in the UK. The cost drivers were adjunctive therapy in France and Germany; stem cell transplant and hospitalization in the UK and Italy, respectively. Conclusion: This analysis improves the understanding of treatment outcomes and costs in PTCL patients in Europe.
No takes yet. Share an insight, caveat, or question.
Kristo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: